Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 25;13:985450. doi: 10.3389/fimmu.2022.985450

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Aiman, Alhamhoom, Ali, Rahman, Rastrelli, Khan, Farooq, Ahmed, Khan and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

In silico immune simulation to predict the immunological potential of designed vaccine MPXV-V2 chimeric peptide predicted by C-ImmSim Server. (A) Increased level of immunoglobin antibodies with a decrease in antigen levels upon vaccine injections. (B) Increased levels of B-cell populations with a decrease in antigen levels upon vaccine injections. (C) Rising B-cell populations after repeated exposure to antigen. (D, E) The increase in the population of T-cytotoxic and T-helper cells upon repeated antigen exposure. (F–H) The population increase of dendritic cells, macrophages, and natural killer cells during the immunization period. (I) Increased concentrations of cytokine and interleukin levels after the repeated antigen exposure. The inset plot shows the danger signal together with leukocyte growth factor IL-2.